Torti Frank — SEC insider filings
SEC reporting owner CIK 1647805. 20 insider filings on record with FilingPulse; latest filed 2026-11-12.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2021-03-23 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 20,000 shares, $116,200 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 1 filing — 3,000,000 shares, $82,039,460 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 40.
- Largest priced transaction: sale of 1,400,000 shares @ $27.42 ($38,388,000) in Roivant Sciences Ltd., filed 2026-02-23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | President and Vant Chair | 7 | — | 3 legs · 3,000,000 sh · $82,039,460 | 21 |
| Immunovant, Inc. (IMVT) | Director | 8 | 1 leg · 20,000 sh · $116,200 | — | 14 |
| Arbutus Biopharma Corp (ABUS) | Director | 4 | — | — | 4 |
| Sio Gene Therapies Inc. (SIOX) | Director | 1 | — | — | 1 |
Insider filings — Torti Frank
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-12 | 4 | Roivant Sciences Ltd. (ROIV) | Other (J): 173,683 @ $40.43 · Other (J): 218,369 @ $41.13 · Other (J): 240,755 @ $41.63 · Other (J): 151,293 @ $42.01 · Other (J): 329,550 @ $40.36 · Other (J): 62,493 @ $41.13 · +1 more | EDGAR |
| 2026-10-02 | 4 | Roivant Sciences Ltd. (ROIV) | Tax withholding (F): 40,309 @ $36.57 | EDGAR |
| 2026-07-02 | 4 | Roivant Sciences Ltd. (ROIV) | Tax withholding (F): 40,310 @ $35.39 | EDGAR |
| 2026-04-09 | 4 | Immunovant, Inc. (IMVT) | Grant/award (A): 174,189 @ $0 · Grant/award (A): 88,325 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Roivant Sciences Ltd. (ROIV) | Tax withholding (F): 160,035 @ $27.70 | EDGAR |
| 2026-02-23 | 4 | Roivant Sciences Ltd. (ROIV) | Option exercise (M): 1,400,000 @ $3.85 · Sale (S): 1,400,000 @ $27.42 · Option exercise (M): 1,012,610 @ $3.85 · Sale (S): 1,012,610 @ $27.15 · Option exercise (M): 587,390 @ $3.85 · Sale (S): 587,390 @ $27.51 · +3 more | EDGAR |
| 2025-12-29 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 175,380 @ $22.45 · Other (J): 64,891 @ $22.47 · Gift (G): 110,489 @ $0 | EDGAR |
| 2025-08-01 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,836,547 @ $0 · Grant/award (A): 11,900,000 @ $0 | EDGAR |
| 2025-04-03 | 4 | Immunovant, Inc. (IMVT) | Grant/award (A): 199,365 @ $0 · Grant/award (A): 93,599 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Arbutus Biopharma Corp (ABUS) | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2024-04-04 | 4 | Immunovant, Inc. (IMVT) | Grant/award (A): 120,400 @ $0 · Grant/award (A): 50,167 (derivative) @ $0 | EDGAR |
| 2023-05-26 | 4 | Arbutus Biopharma Corp (ABUS) | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-04-14 | 4 | Immunovant, Inc. (IMVT) | Grant/award (A): 121,916 @ $0 · Grant/award (A): 158,292 (derivative) @ $0 | EDGAR |
| 2022-09-29 | 4 | Immunovant, Inc. (IMVT) | Purchase (P): 20,000 @ $5.81 | EDGAR |
| 2022-08-19 | 4 | Immunovant, Inc. (IMVT) | Grant/award (A): 225,632 @ $0 · Grant/award (A): 339,296 (derivative) @ $0 | EDGAR |
| 2022-05-26 | 4 | Arbutus Biopharma Corp (ABUS) | Grant/award (A): 41,000 (derivative) @ $0 | EDGAR |
| 2022-01-12 | 4 | Immunovant, Inc. (IMVT) | Grant/award (A): 100,126 @ $0 · Grant/award (A): 329,485 (derivative) @ $0 | EDGAR |
| 2021-06-07 | 4 | Arbutus Biopharma Corp (ABUS) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | Sio Gene Therapies Inc. (SIOX) | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2021-03-23 | 4 | Immunovant, Inc. (IMVT) | Grant/award (A): 19,200 @ $0 · Grant/award (A): 28,900 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-11-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1647805 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs